Floatz logo

Irinotecan

Recurrent Fallopian Tube Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
81/ 100

Competitive context

47 Active assets in the Recurrent Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3BBB
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 3BB
Epirubicin
Roswell Park Cancer Institute
Phase 2BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Brigham and Women's Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →